Targeted Lipolysis vs. Glycemic Disruptions: Deconstructing the Molecular Pathways of AOD-9604. 🔬
In metabolic research, conventional thermogenic protocols often suffer from adverse side effects, including systemic cardiovascular stress or insulin resistance fluctuations. The focus has shifted toward targeted lipid-oxidizing peptides that mimic natural growth hormone pathways without altering insulin receptor binding.
At YearPeak™, aligned with academic synthesis protocols from the Technical University of Munich (TUM), we analyze this lipolytic kinetic through C-terminal human growth hormone domain isolates:
Targeted Lipolysis Catalyst (YearPeak™ AOD-9604 — 5mg): A peptide analogue representing the Tyr-hGH (177-191) C-terminal sequence. It specifically upregulates beta-3 adrenergic receptors on adipocyte membranes, stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat accumulation) without inducing systemic hyperglycemia or IGF-1 spikes.
Cellular Energy Homeostasis (Metabolic Complement): Works synergistically with cellular NAD+ boosters and NNMT inhibitors to optimize mitochondrial lipid oxidation pathways.
Our pure, negative-vacuum freeze-drying workflow ensures zero Trifluoroacetic Acid (TFA) residual interference, preventing metabolic baseline drift during controlled longitudinal studies.
📊 Advance Your Lipid Metabolism Assays (HPLC ≥99% Verified): 🧪 YearPeak™ AOD-9604 Reagents: https://www.yearpeak.com/products/yearpeak-aod-9604-5mg-anti-obesity-peptide?st= 🧪 Explore YearPeak™ Complete Catalog: https://www.yearpeak.com/collections/all?st=
Apply institutional verification code PEAKRESEARCH at checkout for a 10% research credit.














